Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
Form 4 Overview: On 07/17/2025, Ventas, Inc. (VTR) director Sumit Roy automatically received two common-stock equivalent grants generated by dividend-equivalent credits: 49.07 units under the Non-Employee Directors’ Cash Compensation Deferral Plan and 78.961 units under the Non-Employee Directors’ Equity Award Deferral Program, totaling 128.031 shares. The grants were valued at the 07/17/2025 closing price of $65.37 and are payable solely in common stock per the respective plan terms.
Following the credits, Roy’s direct beneficial ownership rose to 20,770.297 shares. No open-market transactions, sales, or derivative exercises were reported, and Table II shows no derivative positions. Because the award is routine, non-cash and represents a de-minimis percentage of Ventas’ outstanding shares, it is unlikely to have an immediate impact on share supply or market sentiment.
Form 144 filing: A beneficial owner named Robert F. Probst has notified Ventas, Inc. (VTR) of his intent to sell up to 29,493 common shares through Merrill Private Wealth on the NYSE around 07/21/2025. At the reference price used in the filing, the block is valued at ≈ $1.95 million.
The notice also lists completed sales by the same seller during the last three months: 69,592 shares on 05/21/25, 17,374 shares on 05/27/25, 168,318 shares on 07/14/25, and 4,098 shares on 07/18/25, for combined gross proceeds of ≈ $16.86 million. Adding the proposed sale, the cumulative disposition reaches 288,875 shares.
With Ventas reporting 451.3 million shares outstanding, the new transaction equals roughly 0.0065 % of total shares, implying minimal dilution or market‐moving impact. The standard Rule 144 certification affirms the seller holds no undisclosed material adverse information.
Form 144 filed for Ventas, Inc. (symbol VTR) discloses the proposed sale of 168,318 common shares by insider Robert F. Probst through Merrill Private Wealth Management. At the reference market price used in the filing, the transaction is valued at $11.0 million. The shares represent roughly 0.04 % of the company’s 451.3 million shares outstanding, indicating a relatively small stake in percentage terms.
The shares were acquired on 14 Jul 2025 via an Employee Stock Ownership Plan (ESOP) and will be sold on or about the same date in a broker-assisted cashless exercise. The filer certifies that no undisclosed material adverse information is known and acknowledges potential liability for false statements.
The filing also details recent insider sales in the prior three months: 69,592 shares on 21 May 2025 for $4.50 million and 17,374 shares on 27 May 2025 for $1.13 million, both by the same seller. Combined with the new notice, total insider disposals disclosed over the period amount to 255,284 shares worth approximately $16.6 million.
While Form 144 does not guarantee that the sale will occur, it signals the insider’s intention and provides advance public notice under SEC Rule 144. Investors often monitor such filings for potential sentiment shifts, even when the absolute percentage of shares is modest.